GOP lawmakers urged the Trump-era FDA/HHS apparatus to ensure clinical trials enroll diverse participants, reframing the policy as aligning trial populations with intended patients rather than pursuing diversity initiatives in staffing or communications. The push emerged after HHS purged references to DEI from agency websites. Supporters of trial diversity argued that broader enrollment improves the relevance of safety and efficacy results for real-world populations. In the lawmakers’ framing, the goal is representation of patients who would use the drugs and devices being tested. The move highlights how regulatory interpretation of trial design and enrollment practices may shift, with potential downstream effects on recruitment timelines, trial cost structures, and protocol requirements across therapeutic areas.